Aparna Balasubramanian1, Neil R MacIntyre2, Robert J Henderson1, Robert L Jensen3, Gregory Kinney4, William W Stringer5, Craig P Hersh6, Russell P Bowler7, Richard Casaburi5, MeiLan K Han8, Janos Porszasz5, R Graham Barr9, Barry J Make7, Robert A Wise1, Meredith C McCormack10. 1. Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD. 2. Division of Pulmonary and Critical Care Medicine, Duke University, Durham, NC. 3. Division of Pulmonary and Critical Care Medicine, University of Utah, Salt Lake City, UT. 4. Department of Epidemiology, Colorado School of Public Health, University of Colorado, Denver, CO. 5. Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA. 6. Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA. 7. Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, CO. 8. Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI. 9. Department of Epidemiology, Columbia University, New York, NY. 10. Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD. Electronic address: mmccor16@jhmi.edu.
Abstract
BACKGROUND: Diffusing capacity of the lung for carbon monoxide (Dlco) is inconsistently obtained in patients with COPD, and the added benefit of Dlco testing beyond that of more common tools is unknown. OBJECTIVE: The goal of this study was to determine whether lower Dlco is associated with increased COPD morbidity independent of emphysema assessed via spirometry and CT imaging. METHODS: Data for 1,806 participants with COPD from the Genetic Epidemiology of COPD (COPDGene) study 5-year visit were analyzed, including pulmonary function testing, quality of life, symptoms, exercise performance, and exacerbation rates. Dlco percent predicted was primarily analyzed as a continuous variable and additionally categorized into four groups: (1) Dlco and FEV1 > 50% (reference); (2) only Dlco ≤ 50%; (3) only FEV1 ≤ 50%; and (4) both ≤ 50% predicted. Outcomes were modeled by using multivariable linear and negative binomial regression, including emphysema and FEV1 percent predicted among other confounders. RESULTS: In multivariable analyses, every 10% predicted decrease in Dlco was associated with symptoms and quality of life (COPD Assessment Test, 0.53 [P < .001]; St. George's Respiratory Questionnaire, 1.67 [P < .001]; Medical Outcomes Study Short Form 36 Physical Function, -0.89 [P < .001]), exercise performance (6-min walk distance, -45.35 feet; P < .001), and severe exacerbation rate (rate ratio, 1.14; P < .001). When categorized, severe impairment in Dlco alone, FEV1 alone, or both Dlco and FEV1 were associated with significantly worse morbidity compared with the reference group (P < .05 for all outcomes). CONCLUSIONS: Impairment in Dlco was associated with increased COPD symptoms, reduced exercise performance, and severe exacerbation risk even after accounting for spirometry and CT evidence of emphysema. These findings suggest that Dlco should be considered for inclusion in future multidimensional tools assessing COPD.
BACKGROUND: Diffusing capacity of the lung for carbon monoxide (Dlco) is inconsistently obtained in patients with COPD, and the added benefit of Dlco testing beyond that of more common tools is unknown. OBJECTIVE: The goal of this study was to determine whether lower Dlco is associated with increased COPD morbidity independent of emphysema assessed via spirometry and CT imaging. METHODS: Data for 1,806 participants with COPD from the Genetic Epidemiology of COPD (COPDGene) study 5-year visit were analyzed, including pulmonary function testing, quality of life, symptoms, exercise performance, and exacerbation rates. Dlco percent predicted was primarily analyzed as a continuous variable and additionally categorized into four groups: (1) Dlco and FEV1 > 50% (reference); (2) only Dlco ≤ 50%; (3) only FEV1 ≤ 50%; and (4) both ≤ 50% predicted. Outcomes were modeled by using multivariable linear and negative binomial regression, including emphysema and FEV1 percent predicted among other confounders. RESULTS: In multivariable analyses, every 10% predicted decrease in Dlco was associated with symptoms and quality of life (COPD Assessment Test, 0.53 [P < .001]; St. George's Respiratory Questionnaire, 1.67 [P < .001]; Medical Outcomes Study Short Form 36 Physical Function, -0.89 [P < .001]), exercise performance (6-min walk distance, -45.35 feet; P < .001), and severe exacerbation rate (rate ratio, 1.14; P < .001). When categorized, severe impairment in Dlco alone, FEV1 alone, or both Dlco and FEV1 were associated with significantly worse morbidity compared with the reference group (P < .05 for all outcomes). CONCLUSIONS: Impairment in Dlco was associated with increased COPD symptoms, reduced exercise performance, and severe exacerbation risk even after accounting for spirometry and CT evidence of emphysema. These findings suggest that Dlco should be considered for inclusion in future multidimensional tools assessing COPD.
Authors: M R Miller; J Hankinson; V Brusasco; F Burgos; R Casaburi; A Coates; R Crapo; P Enright; C P M van der Grinten; P Gustafsson; R Jensen; D C Johnson; N MacIntyre; R McKay; D Navajas; O F Pedersen; R Pellegrino; G Viegi; J Wanger Journal: Eur Respir J Date: 2005-08 Impact factor: 16.671
Authors: Sanja Stanojevic; Brian L Graham; Brendan G Cooper; Bruce R Thompson; Kim W Carter; Richard W Francis; Graham L Hall Journal: Eur Respir J Date: 2017-09-11 Impact factor: 16.671
Authors: Lorriana E Leard; Are M Holm; Maryam Valapour; Allan R Glanville; Sandeep Attawar; Meghan Aversa; Silvia V Campos; Lillian M Christon; Marcelo Cypel; Göran Dellgren; Matthew G Hartwig; Siddhartha G Kapnadak; Nicholas A Kolaitis; Robert M Kotloff; Caroline M Patterson; Oksana A Shlobin; Patrick J Smith; Amparo Solé; Melinda Solomon; David Weill; Marlies S Wijsenbeek; Brigitte W M Willemse; Selim M Arcasoy; Kathleen J Ramos Journal: J Heart Lung Transplant Date: 2021-07-24 Impact factor: 13.569
Authors: Aparna Balasubramanian; Todd M Kolb; Rachel L Damico; Paul M Hassoun; Meredith C McCormack; Stephen C Mathai Journal: Chest Date: 2020-03-14 Impact factor: 9.410
Authors: Brianna P Matthew; Amir M Hasani; Yun-Ching Chen; Mehdi Pirooznia; Mario Stylianou; Shirley F Rollison; Tania R Machado; Nora M Quade; Amanda M Jones; Patricia Julien-Williams; Angelo Taveira-DaSilva; Marcus Y Chen; Joel Moss; Han Wen Journal: Chest Date: 2021-02-05 Impact factor: 9.410
Authors: Juan P de-Torres; Denis E O'Donnell; Jose M Marín; Carlos Cabrera; Ciro Casanova; Marta Marín; Ana Ezponda; Borja G Cosio; Cristina Martinez; Ingrid Solanes; Antonia Fuster; J Alberto Neder; Jessica Gonzalez-Gutierrez; Bartolome R Celli Journal: Chest Date: 2021-04-24 Impact factor: 10.262
Authors: Amanda K Jan; Julia V Moore; Richard J Wang; Maggie Mcging; Carly K Farr; Daniela Moisi; Marlena Hartman-Filson; Robert Kerruish; Diane Jeon; Eula Lewis; Kristina Crothers; Michael M Lederman; Peter W Hunt; Laurence Huang Journal: AIDS Date: 2021-06-01 Impact factor: 4.632
Authors: Ken M Kunisaki; Mehdi Nouraie; Robert L Jensen; Dong Chang; Gypsyamber D'Souza; Meghan E Fitzpatrick; Meredith C McCormack; Valentina Stosor; Alison Morris Journal: AIDS Date: 2020-07-01 Impact factor: 4.632